Skip to main content
SpringerLink
Log in
Book cover

Acute Promyelocytic Leukemia pp 205–219Cite as

Monoclonal Antibody Therapy of APL

  • Chapter

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 313))

Abstract

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) for which a number of targeted therapies have been developed. The “targets” have included both genotypic and phenotypic features of the disease. The application of monoclonal antibodies (MAbs) to this disease to date have been limited to a relatively small number of studies where this therapy has been used to supplement effective approaches to the disease. The preliminary results have been promising, and further development of this modality as an effective adjunct to existing treatment regimens will most certainly occur in the near future.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rowley J, Golomb HM, Dougherty C (1997) 15/17 trans-location, a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1:549–550

    Google Scholar 

  2. Larsen RA, Kondo K, Vardiman JW, et al (1984) Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76:827–841

    Article  Google Scholar 

  3. de Thë H, Chomienne C, Lanotte M, et al (1990) The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347:558–561

    Article  PubMed  Google Scholar 

  4. Kakizuka A, Miller WH, Umesono K, et al (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PLL. Cell 66:663

    Article  CAS  PubMed  Google Scholar 

  5. de Thë H, Lavau C, Marchio A, et al (1991) The PML/RARa fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675

    Article  PubMed  Google Scholar 

  6. Melnick A, Licht JD (1999) Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167–3215

    CAS  PubMed  Google Scholar 

  7. Pandolfi PP, Alcalay M, Fagioli M, et al (1992) Genomic variability and alternative splicing generate multiple PML-RARα transcripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukemia. EMBO J 11:1397–1407

    CAS  PubMed  Google Scholar 

  8. Vahdat L, Maslak P, Miller WH, et al (1994) Early mortality and retinoic acid syndrome in acute promyelocytic leukemia: impact of leucocytosis, low-dose chemotherapy, PML/RARα isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843–3849

    CAS  PubMed  Google Scholar 

  9. Jurcic JG, Nimer SD, Scheinberg D, et al (2001) Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 98:2651–2656

    Article  CAS  PubMed  Google Scholar 

  10. Gallagher RE, Willman CL, Slack JL, et al (1997) Association of PML/RARα fusion mRNA type with pre-treatment characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 90:1656–1663

    CAS  PubMed  Google Scholar 

  11. Hong SH, David G, Wong CW, et al (1997) SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα on coproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:9028–9033

    Article  CAS  PubMed  Google Scholar 

  12. Guidez F, Ivins S, Zhu J, et al (1998) Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91:2634–2642

    CAS  PubMed  Google Scholar 

  13. Heinzel T, Lavinski R, Mullen T, et al (1997) A complex containing N-CoR, mSin3 and histone deacetylase, mediates transcriptional repression. Nature 387:43–48

    Article  CAS  PubMed  Google Scholar 

  14. Lin RJ, Nagy L, Inoue S, et al (1998) Role of histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811–814

    Article  CAS  PubMed  Google Scholar 

  15. Uteley RT, Ikeda K, Grant PA, et al (1998) Transcriptional activators direct histone acetyltransferase complexed to nucleosomes. Nature 30:498–502

    Google Scholar 

  16. Chen Z, Brand NJ, Chen A, et al (1993) Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation association with acute promyelocytic leukaemia. EMBO J 12:1161–1167

    CAS  PubMed  Google Scholar 

  17. Licht JD, Chomienne C, Goy A, et al (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with trans-location (11;17). Blood 85:1083–1094

    CAS  PubMed  Google Scholar 

  18. Redner RL, Chen JD, Rush EA, et al (2000) The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. Blood 95:2683–2690

    CAS  PubMed  Google Scholar 

  19. Wells RA, Catzavelos C, Kamel-Reid S (1997) Fusion of retinoic acid receptor α to NUMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 17:109–113

    Article  CAS  PubMed  Google Scholar 

  20. Arnould C, Phillippe C, Bourdon V, et al (1999) The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 8:1741–1749

    Article  CAS  PubMed  Google Scholar 

  21. He LZ, Guidez F, Tribioli C, et al (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18:126–135

    Article  CAS  PubMed  Google Scholar 

  22. Miller WH Jr, Kakizuka A, Frankel SR, et al (1992) Reverse transcription polymerase chain reaction for the re-arranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:2694–2698

    Article  CAS  PubMed  Google Scholar 

  23. Lo Coco F, Diverio D, Pandolfi PP, et al (1992) Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 340:1437–1438

    Article  PubMed  Google Scholar 

  24. Miller WH Jr, Levine K, De Blasio A, et al (1993) Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction. Blood 82:1689–1694

    CAS  PubMed  Google Scholar 

  25. Grimwade D, Howe K, Langabeer S, et al (1996) Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse. Leukemia 10:61–66

    CAS  PubMed  Google Scholar 

  26. Diverio D, Rossi V, Avvisati G, et al (1998) Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial. Blood 92:784–789

    CAS  PubMed  Google Scholar 

  27. Bennett JM, Catovsky D, Daniel MT, et al (1976) Proposal for the classification of the acute leukaemias (FAB Cooperative Group). Br J Haematol 33:451–458

    CAS  PubMed  Google Scholar 

  28. Golomb HM, Rowley JD, Vardiman JW, et al (1980)Microgranular acute promyelocytic leukaemia: a distinct clinical, ultrastructural, and cytogenetic entity. Blood 55:253–259

    CAS  PubMed  Google Scholar 

  29. Bennett JM, Catovsky D, Daniel MT, et al (1980) A variant form of hypergranular promyelocytic leukemia (M3). Br J Haematol 44:169–170

    CAS  PubMed  Google Scholar 

  30. Sainty D, Liso V, Cantu-Rajnoldi A, et al (2000)A new morphological classification system for acute promyelocytic distinguishes cases with underlying PLZF-RARα rearrangements. Blood 96:1287–1296

    CAS  PubMed  Google Scholar 

  31. Das Gupta A, Sapre RS, Shah AS, et al (1989) Cytochemical and immunophenotypic heterogeneity in acute promyelocytic leukemia. Acta Haematol 81:5–9

    PubMed  Google Scholar 

  32. Paietta E, Andersen J, Gallagher R, et al (1994) The immunophenotype of acute promyelocytic leukemia (APL): an ECOG. Leukemia 8:1108–1112

    CAS  PubMed  Google Scholar 

  33. Erbert WN, Asbahr H, Rule SA, et al (1994) Unique immunophenotype of acute promyelocytic leukaemia as defined by CD9 and CD68 antibodies. Br J Haematol 88:101–104

    Google Scholar 

  34. Cunningham I, Gee TS, Reich LM, et al (1989) Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 73:1116–1122

    CAS  PubMed  Google Scholar 

  35. Kantarjian H, Keating MJ, Walters RS, et al (1986) Acute promyelocytic leukemia: MD Anderson Hospital experience. Am J Med 80:789–797

    Article  CAS  PubMed  Google Scholar 

  36. Di Bona E, Avvisati G, Castaman G, et al (2000) Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukemia. Br J Haematol 108:689–695

    Article  PubMed  Google Scholar 

  37. Head D, Kopecky KJ, Weick J, et al (1995) Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717–1728

    CAS  PubMed  Google Scholar 

  38. Estey E, Thall PF, Pierce S, et al (1997) Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483–490

    CAS  PubMed  Google Scholar 

  39. Huang ME, Ye YC, Chen SR, et al (1988) Use of all-trans retinoic acid in treatment of acute promyelocytic leukemia. Blood 72:567–572

    CAS  PubMed  Google Scholar 

  40. Warrell RP Jr, Frankel SR, Miller WH Jr, et al (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoid acid). N Engl J Med 324:1385–1393

    PubMed  Google Scholar 

  41. Huang ME, Ye YC, Chen SR, et al (1987) All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia-Report of 6 cases. Chin Med J 100:949–953

    CAS  PubMed  Google Scholar 

  42. Fenaux P, Le Dely MC, Castaigne S, et al (1993) Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 82:3241–3249

    CAS  PubMed  Google Scholar 

  43. Lo Coco F, Avvisati G, Diverio D, et al (1991) Molecular evaluation of response to all-trans retinoic acid therapy in patients with acute promyelocytic leukemia. Blood 77:1657–1661

    PubMed  Google Scholar 

  44. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr (1992) The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 117:292–296

    CAS  PubMed  Google Scholar 

  45. Frankel SR, Eardley A, Heller G, et al (1994) All-trans retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann Intern Med 120:278–286

    CAS  PubMed  Google Scholar 

  46. Warrell RP Jr, Maslak P, Eardley A, et al (1994) Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 8:929–933

    PubMed  Google Scholar 

  47. Castaigne S, Chomienne C, Daniel MT, et al (1990) All-trans retinoic acid as a differentiating therapy for acute promyelocytic leukemias. I. Clinical Results. Blood 76:1704–1713

    CAS  PubMed  Google Scholar 

  48. Avvisati G (1998) AIDA Protocol: the Italian way of treating APL (Abrstr). Br J Haematol 102:593a

    Google Scholar 

  49. Tallman MS, Andersen JW, Schiffer CA, et al (1997) All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021–1028

    Article  CAS  PubMed  Google Scholar 

  50. Fenaux P, Chastang C, Chevret S, et al (1999) A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94:1192–1200

    CAS  PubMed  Google Scholar 

  51. Avvisati G, Petti MC, Lo Coco F, et al (2003) AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act (Abstr). Blood 102:487

    Google Scholar 

  52. Lobe I, Rigal-Huget FR, Vekoff A, et al (2003) Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia 17:1600–1604

    Article  CAS  PubMed  Google Scholar 

  53. Andrews RG, Takahashi M, Segal GM, et al (1986) The L4F3 antigen is expressed by unipotent colony-forming cells but not by their precursors. Blood 68:1030–1035

    CAS  PubMed  Google Scholar 

  54. Scheinberg DA, Lovett D, Divgi CR, et al (1991) A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478–490

    CAS  PubMed  Google Scholar 

  55. Jurcic JG, Caron PC, Miller WH Jr, et al (1995) Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 9:244–248

    CAS  PubMed  Google Scholar 

  56. Caron PC, Co MS, Bull MK, et al (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 52:6761–6767

    CAS  PubMed  Google Scholar 

  57. Caron PC, Jurcic JG, Scott AM, et al (1994) A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 83:1760–1768

    CAS  PubMed  Google Scholar 

  58. Xu Y, Scheinberg DA (1995) Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clin Cancer Res 1:1179–1187

    CAS  PubMed  Google Scholar 

  59. Caron PC, Dumont L, Scheinberg DA (1998) Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 4:1421–1428

    CAS  PubMed  Google Scholar 

  60. Feldman E, Kalaycio M, Weiner G, et al (2003) Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 17:314–318

    Article  CAS  PubMed  Google Scholar 

  61. Feldman E, Stone RM, Brandwein J, et al (2002) Phase III randomized trial of an anti-CD33 monoclonal antibody (HuM195) in combination with chemotherapy compared to chemotherapy alone in adults with refractory or first-relapse acute myeloid leukemia (AML) (Abstr). Proc Am Soc Clin Oncol 21:261a

    Google Scholar 

  62. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA (2000) Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 6:372–380

    CAS  PubMed  Google Scholar 

  63. Mulford DA, Maslak PG, Weiss MA, Scheinberg DA, Jurcic JG (2003) Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy (Abrstr). Blood 102:619a–620a

    Google Scholar 

  64. Sievers EL, Appelbaum FR, Spielberger RT, et al (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678–3684

    CAS  PubMed  Google Scholar 

  65. Sievers EL, Larson RA, Staudtmauer EA, et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244–3254

    CAS  PubMed  Google Scholar 

  66. Amadori S, Suciu S, Willemze R, Mandelli F, Selleslag D, Stauder R, Ho A, Denzlinger C, Leone G, Fabris P, Muus P, Vignetti M, Hagemeijer A, Beeldens F, Anak O, De Witte T; EORTC leukemia group; GIMEMA leukemia group (2004) Sequential administration of gemtuzumab ozogamcin and convential chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 89:950–956

    CAS  PubMed  Google Scholar 

  67. Sievers E, Larson R, Estey E, et al (2002) Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematpoietic stemcell transplantation (Abstr). Blood 100:89a

    Article  Google Scholar 

  68. Rajvanshi P, Schulman H, Sievers E, et al (2002) Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 99:10–14

    Article  Google Scholar 

  69. Giles FJ, Kantarjian HM, Kornblau SM, et al (2001) Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92:406–413

    Article  CAS  PubMed  Google Scholar 

  70. Takeshita A, Shinjo K, Naito K, et al (2005) Efficacy of gemtuzumab ozogamicin on ATRA-and arsenic resistant acute promyelocytic leukemia (APL) cells. Leukemia 19:1306–1311

    Article  CAS  PubMed  Google Scholar 

  71. Estey E, Giles FJ, Beran M, et al (2002) Experience with gemtuzumab ozogamycin (“myelotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99:4222–4224

    Article  CAS  PubMed  Google Scholar 

  72. Lo-Coco F, Cimino G, Breccia M, et al (2004) Gemtuzumab ozogamicin (Myelotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104:1995–1999

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, 10021, USA

    P. G. Maslak, J. G. Jurcic & D. A. Scheinberg

Authors
  1. P. G. Maslak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. G. Jurcic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. A. Scheinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Sloan-Kettering-Institute, 1275 York Avenue, New York, New York, 10021, USA

    Pier Paolo Pandolfi MD, Ph.D.

  2. The Scripps Research Institute, 10550 North Torreye Pines Road, La Jolla, CA, 92037, USA

    Peter K. Vogt Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Maslak, P.G., Jurcic, J.G., Scheinberg, D.A. (2007). Monoclonal Antibody Therapy of APL. In: Pandolfi, P.P., Vogt, P.K. (eds) Acute Promyelocytic Leukemia. Current Topics in Microbiology and Immunology, vol 313. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34594-7_11

Download citation

Publish with us

Policies and ethics

Search

Navigation